A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Refractory Multiple MyelomaLast Updated:October 7, 2016Terminated
Hide Studies Not Open or Pending
Condition(s):Refractory Multiple MyelomaLast Updated:October 7, 2016Terminated
Condition(s):Relapsed and/or Refractory Multiple Myeloma; Relapsed and/or Refractory Non Hodgkin LymphomaLast Updated:April 14, 2023Active, not recruiting
Condition(s):Multiple Myeloma; Neoplasm, Plasma Cell; Multiple Myeloma in RelapseLast Updated:April 18, 2023Recruiting
Condition(s):Multiple MyelomaLast Updated:April 26, 2022Completed
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:November 4, 2020Completed
Condition(s):Multiple Myeloma; Multiple Myeloma in Relapse; Neoplasm, Plasma CellLast Updated:April 18, 2023Recruiting
Condition(s):Relapsed Multiple Myeloma; Refractory Multiple MyelomaLast Updated:March 10, 2023Completed
Condition(s):Multiple Myeloma; Neoplasm, Plasma Cell; Multiple Myeloma in RelapseLast Updated:April 18, 2023Recruiting
Condition(s):Relapsed and Refractory Multiple MyelomaLast Updated:March 30, 2023Recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:May 6, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.